Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Gilbert

Showing results (731-740 of 752) with videos related to

Pageof 76
Sort By:
Controlled Clinical Trials|February 24, 2001
Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening TrialP C Prorok, G L Andriole, R S Bresalier, et al.
Oncotarget|May 3, 2018
ONC201 kills breast cancer cells <i>in vitro</i> by targeting mitochondriaYoshimi Endo Greer, Natalie Porat-Shliom, Kunio Nagashima, et al.
Evolution & Development|May 13, 2015
The significance and scope of evolutionary developmental biology: a vision for the 21st centuryArmin P Moczek, Karen E Sears, Angelika Stollewerk, et al.
Journal of Medicinal Chemistry|July 14, 2000
In vitro and in vivo evaluation of dihydropyrimidinone C-5 amides as potent and selective alpha(1A) receptor antagonists for the treatment of benign prostatic hyperplasiaJ C Barrow, P G Nantermet, H G Selnick, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma ExposureMichael T Rudd, John A McCauley, John W Butcher, et al.
The New England Journal of Medicine|June 29, 2022
Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) InfectionJulie Boucau, Caitlin Marino, James Regan, et al.
Medrxiv : the Preprint Server for Health Sciences|March 9, 2022
Duration of viable virus shedding in SARS-CoV-2 omicron variant infectionJulie Boucau, Caitlin Marino, James Regan, et al.
Journal of Medicinal Chemistry|February 19, 2010
Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitorJohn A McCauley, Charles J McIntyre, Michael T Rudd, et al.
Open Forum Infectious Diseases|June 15, 2026
Prevalence and Correlates of Steatotic Liver Disease Among People With HIV in UgandaProssy Bibangambah, Moses Acan, Brian Ghoshhajra, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 7, 2021
Determining the Incidence of Asymptomatic SARS-CoV-2 Among Early Recipients of COVID-19 Vaccines (DISCOVER-COVID-19): A Prospective Cohort Study of Healthcare Workers Before, During and After VaccinationCrystal M North, Amy Barczak, Robert H Goldstein, et al.
Pageof 76

Showing results (731-740 of 752) with videos related to

Sort By:
Pageof 76
Controlled Clinical Trials|February 24, 2001
Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening TrialP C Prorok, G L Andriole, R S Bresalier, et al.
Oncotarget|May 3, 2018
ONC201 kills breast cancer cells <i>in vitro</i> by targeting mitochondriaYoshimi Endo Greer, Natalie Porat-Shliom, Kunio Nagashima, et al.
Evolution & Development|May 13, 2015
The significance and scope of evolutionary developmental biology: a vision for the 21st centuryArmin P Moczek, Karen E Sears, Angelika Stollewerk, et al.
Journal of Medicinal Chemistry|July 14, 2000
In vitro and in vivo evaluation of dihydropyrimidinone C-5 amides as potent and selective alpha(1A) receptor antagonists for the treatment of benign prostatic hyperplasiaJ C Barrow, P G Nantermet, H G Selnick, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma ExposureMichael T Rudd, John A McCauley, John W Butcher, et al.
The New England Journal of Medicine|June 29, 2022
Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) InfectionJulie Boucau, Caitlin Marino, James Regan, et al.
Medrxiv : the Preprint Server for Health Sciences|March 9, 2022
Duration of viable virus shedding in SARS-CoV-2 omicron variant infectionJulie Boucau, Caitlin Marino, James Regan, et al.
Journal of Medicinal Chemistry|February 19, 2010
Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitorJohn A McCauley, Charles J McIntyre, Michael T Rudd, et al.
Open Forum Infectious Diseases|June 15, 2026
Prevalence and Correlates of Steatotic Liver Disease Among People With HIV in UgandaProssy Bibangambah, Moses Acan, Brian Ghoshhajra, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 7, 2021
Determining the Incidence of Asymptomatic SARS-CoV-2 Among Early Recipients of COVID-19 Vaccines (DISCOVER-COVID-19): A Prospective Cohort Study of Healthcare Workers Before, During and After VaccinationCrystal M North, Amy Barczak, Robert H Goldstein, et al.
Pageof 76